Neuland Labs.

Why is Neuland Laboratories Ltd falling/rising?

As of 20-Aug, Neuland Laboratories Ltd's stock price has risen to 23,562.25, reflecting a year-to-date increase of 55.11% and a 71.77% rise over the past year, significantly outperforming the Sensex. Strong fundamentals, including a high return on equity and positive financial results, support this upward trend despite a recent decline in investor participation.

As of 20-Aug, Neuland Laboratories Ltd is experiencing a rise in its stock price, currently at 23,562.25, reflecting an increase of 265.4 (1.14%). This upward movement can be attributed to several factors. Firstly, the stock has shown strong performance over various time frames, with a year-to-date increase of 55.11% and a remarkable 71.77% rise over the past year, significantly outperforming the Sensex, which has declined by 9.02% during the same period. <BR><BR>Additionally, the stock is close to its 52-week high, being only 1.22% away from the peak of Rs 23,850. Today's performance indicates that it has outperformed its sector by 0.89%, and it has gained after two consecutive days of decline, suggesting a trend reversal. Furthermore, Neuland Laboratories is trading above its moving averages across multiple time frames, indicating positive momentum.<BR><BR>The company's fundamentals also support this rise, with a high return on equity (ROE) of 16.00% and a low debt-to-equity ratio of 0.07, showcasing strong management efficiency and financial health. The recent positive financial results, including a 26.86% growth in net sales and substantial increases in profit before tax and profit after tax, further bolster investor confidence. High institutional holdings at 37.6%, which have increased by 1.3% over the previous quarter, indicate strong backing from knowledgeable investors.<BR><BR>However, it is worth noting that there has been a decline in investor participation, with delivery volume falling by 59.13% against the 5-day average. Despite this, the overall positive financial indicators and consistent returns over the last three years contribute to the stock's rising price.

Which are the latest news on Neuland Labs.?

Who are in the management team of Neuland Labs.?

The management team of Neuland Labs includes D R Rao (Executive Chairman), D Sucheth Rao (Vice Chairman & CEO), D Saharsh Rao (Vice Chairman & Managing Director), and Sarada Bhamidipati (Company Secretary & Compliance Officer), along with several independent directors on the Board. This team is responsible for the company's strategic direction and governance.

The management team of Neuland Labs includes the following key members:<BR><BR>1. D R Rao - Executive Chairman<BR>2. D Sucheth Rao - Vice Chairman & CEO<BR>3. D Saharsh Rao - Vice Chairman & Managing Director<BR>4. Sarada Bhamidipati - Company Secretary & Compliance Officer<BR><BR>Additionally, the Board of Directors comprises several independent directors:<BR>- H Dhanrajgir<BR>- P V Maiya<BR>- Christopher M Cimarusti<BR>- Bharati Rao<BR>- Nirmala Murthy<BR>- Homi Rustam Khusrokhan<BR>- Prasad R Menon<BR>- Sugata Sircar<BR>- Pallavi Joshi Bakhru<BR><BR>This team plays a crucial role in guiding the strategic direction and governance of the company.

What does Neuland Labs. do?

Neuland Laboratories Ltd manufactures and sells bulk drugs in the Pharmaceuticals & Biotechnology industry, categorized as a Small Cap company with a market cap of INR 29,007 Cr. As of June 2026, it reported net sales of 642 Cr and a net profit of 148 Cr.

Overview:<BR>Neuland Laboratories Ltd is engaged in the manufacturing and selling of bulk drugs within the Pharmaceuticals & Biotechnology industry and is categorized as a Small Cap company.<BR><BR>History:<BR>Incorporated on January 7, 1984, Neuland Laboratories Ltd was promoted by Davuluri Sucheth Rao. The company merged with Neuland Drugs & Pharmaceuticals Pvt. Ltd. in April 1992. The latest quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot:<BR>Net Sales: 642 Cr (Quarterly Results - Jun 2026) <BR>Net Profit: 148 Cr (Quarterly Results - Jun 2026) <BR>Market Cap: INR 29,007 Cr (Small Cap)<BR><BR>Key Metrics:<BR>P/E: 60.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.15% <BR>Debt-Equity: -0.03 <BR>Return on Equity: 19.42% <BR>Price to Book: 15.41 <BR><BR>Contact Details:<BR>Address: 11 Th Floor Phoenix IVY Buildi, Plot No 573A-III Road No 82 Hyderabad Telangana : 500035 <BR>Tel: 91-40-30211600 <BR>Email: ir@neulandlabs.com <BR>Website: http://www.neulandlabs.com

Who are the peers of the Neuland Labs.?

Neuland Labs. peers include Ajanta Pharma, Glaxosmi. Pharma, Emcure Pharma, Sai Life, Wockhardt, Piramal Pharma, Acutaas Chemical, Pfizer, and Granules India. Neuland Labs. has a 1-year return of 78.35%, with excellent management and growth ratings, while Acutaas Chemical leads with a 136.06% return.

Peers: The peers of Neuland Labs. are Ajanta Pharma, Glaxosmi. Pharma, Emcure Pharma, Sai Life, Wockhardt, Piramal Pharma, Acutaas Chemical, Pfizer, and Granules India.<BR><BR>Quality Snapshot: Excellent management risk is observed at Ajanta Pharma and Glaxosmi. Pharma, while Good management risk is found at Emcure Pharma, Neuland Labs., Acutaas Chemical, and Pfizer. Average management risk is noted at Sai Life and Wockhardt, and Average management risk is also present at Piramal Pharma. Growth is Excellent at Emcure Pharma, Neuland Labs., Sai Life, and Acutaas Chemical, while Below Average growth is seen at Ajanta Pharma, Glaxosmi. Pharma, and Piramal Pharma. Good growth is noted at Wockhardt and Granules India. Capital Structure is Excellent at Ajanta Pharma, Glaxosmi. Pharma, Neuland Labs., Sai Life, Emcure Pharma, Acutaas Chemical, and Pfizer, while Below Average capital structure is found at Wockhardt and Piramal Pharma.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Acutaas Chemical at 136.06%, while Glaxosmi. Pharma has the lowest at -3.93%. Neuland Labs. has a 1-year return of 78.35%, which is significantly higher than Glaxosmi. Pharma but lower than Acutaas Chemical. Additionally, the peers with negative six-month returns are Glaxosmi. Pharma and Pfizer.

How big is Neuland Labs.?

As of 14th August, Neuland Laboratories Ltd has a market capitalization of 29,905.44 Cr, with recent net sales of 2,371.81 Cr and a net profit of 497.76 Cr.

As of 14th August, Neuland Laboratories Ltd has a market capitalization of 29,905.44 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, Neuland Labs reported Net Sales of 2,371.81 Cr and a Net Profit of 497.76 Cr.<BR><BR>The latest annual period for the balance sheet is March 2026, with Shareholder's Funds amounting to 1,874.47 Cr and Total Assets of 2,930.14 Cr.

Are Neuland Laboratories Ltd latest results good or bad?

Neuland Laboratories Ltd's latest results show impressive year-on-year growth with a 119.16% increase in net sales and a 962.37% rise in net profit. However, there are concerns due to a 17.35% revenue decline and a 30.56% drop in net profit compared to the previous quarter, indicating potential challenges ahead.

Neuland Laboratories Ltd's latest results present a mixed picture. On one hand, the company reported a remarkable year-on-year net sales growth of 119.16%, reaching ₹641.58 crores, and a net profit surge of 962.37% to ₹147.67 crores. These figures reflect a strong recovery from the previous year's weak performance.<BR><BR>However, the sequential performance shows concerning signs. There was a significant revenue decline of 17.35% compared to the previous quarter, along with a 30.56% drop in net profit. Additionally, the operating margin decreased from 39.59% in the last quarter to 34.74%, indicating volatility in earnings and raising questions about the sustainability of such growth.<BR><BR>Overall, while the year-on-year growth figures are impressive and suggest operational improvements, the sequential declines and margin compression highlight potential challenges ahead. Investors should consider these factors when evaluating the company's performance and future prospects.

Should I buy, sell or hold Neuland Laboratories Ltd?

When is the next results date for Neuland Laboratories Ltd?

Neuland Laboratories Ltd will announce its results on 05 August 2026.

Neuland Laboratories Ltd is scheduled to declare its results on 05 August 2026.

How has been the historical performance of Neuland Labs.?

Neuland Labs experienced fluctuating financial performance, with net sales and operating income peaking at 1,558.58 Cr in March 2024 before declining to 1,476.84 Cr in March 2025, while profit metrics also decreased. However, total assets and cash flow from operating activities improved during the same period.

Answer:<BR>The historical performance of Neuland Labs shows a fluctuating trend in key financial metrics over the years.<BR><BR>Breakdown:<BR>Neuland Labs' net sales peaked at 1,558.58 Cr in March 2024 but declined to 1,476.84 Cr by March 2025. The total operating income followed a similar pattern, reaching 1,558.58 Cr in March 2024 before dropping to 1,476.84 Cr in March 2025. Raw material costs increased from 360.44 Cr in March 2019 to 574.81 Cr in March 2025, while employee costs rose from 110.46 Cr in March 2019 to 272.00 Cr in March 2025. Operating profit (PBDIT) saw a decline from 475.13 Cr in March 2024 to 343.78 Cr in March 2025, with a corresponding decrease in profit before tax from 401.44 Cr to 346.33 Cr. Profit after tax also fell from 300.08 Cr in March 2024 to 260.11 Cr in March 2025. The company's total assets increased significantly from 1,230.98 Cr in March 2020 to 2,179.88 Cr in March 2025, while total liabilities rose from 1,230.98 Cr to 2,179.88 Cr in the same period. Cash flow from operating activities improved from 261.00 Cr in March 2024 to 317.00 Cr in March 2025, contributing to a net cash inflow of 44.00 Cr by March 2025.

Is Neuland Labs. technically bullish or bearish?

As of October 8, 2025, the trend has shifted to bullish with strong indicators like the weekly MACD and Bollinger Bands supporting this view, although caution is advised due to mildly bearish monthly MACD and KST signals.

As of 8 October 2025, the technical trend has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this view. The weekly MACD is bullish, and both the weekly and monthly Bollinger Bands are bullish. Daily moving averages also confirm a bullish trend. However, the monthly MACD and KST are mildly bearish, indicating some caution. Overall, the strength of the bullish trend is reinforced by the positive returns over various periods, particularly the impressive 3-year and 5-year returns compared to the Sensex.

Is Neuland Labs. overvalued or undervalued?

As of November 8, 2023, Neuland Labs is considered very expensive with a PE ratio of 83.55, significantly higher than its peers, indicating potential overvaluation despite a strong 1-year stock return of 105.28%.

As of 8 November 2023, Neuland Labs' valuation grade has moved from expensive to very expensive, indicating a significant increase in perceived overvaluation. The company is currently assessed as overvalued, with a PE ratio of 83.55, a Price to Book Value of 10.97, and an EV to EBITDA ratio of 51.10. These metrics suggest that the stock is trading at a premium compared to its earnings and book value.<BR><BR>In comparison to its peers, Neuland Labs stands out with a notably higher PE ratio than Sun Pharma, which has a PE of 35.25, and Divi's Lab at 79.33. Other peers like Cipla and Dr. Reddy's Labs exhibit much lower valuations, with PE ratios of 22.99 and 19.49, respectively. Despite recent strong stock performance, with a 1-year return of 105.28% compared to the Sensex's 7.58%, the elevated valuation metrics indicate that Neuland Labs may not sustain its current price levels in the long term.

Who are the top shareholders of the Neuland Labs.?

The top shareholders of Neuland Labs include the Davuluri Ownership Trust with 25.98%, individual investors with 25.86%, and 189 Foreign Institutional Investors holding 22.11%. The highest public shareholder is Malabar India Fund Limited at 5.76%, with no pledged promoter holdings reported.

The top shareholders of Neuland Labs include the Davuluri Ownership Trust, which holds the largest stake at 25.98%. Additionally, individual investors collectively own 25.86% of the company. Among institutional investors, 189 Foreign Institutional Investors (FIIs) hold 22.11%, while mutual funds are represented by 23 schemes with a combined holding of 7.43%. The highest public shareholder is Malabar India Fund Limited, with a stake of 5.76%. There are no pledged promoter holdings reported.

Has Neuland Labs. declared dividend?

Yes, Neuland Laboratories Ltd has declared a dividend of 140% (₹14 per share) with an ex-date of July 12, 2024. While recent returns have been volatile, the company has shown substantial long-term growth, with a total return of 3148.39% over the past five years.

Neuland Laboratories Ltd has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 140%<BR>- Amount per share: 14<BR>- Ex-date: 12 Jul 24<BR><BR>Dividend Yield: 0.12%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -25.58%, with a dividend return of 0%, resulting in a total return of -25.58%.<BR><BR>Over the past year, the price return was 112.28%, the dividend return was 0.22%, leading to a total return of 112.5%.<BR><BR>In the 2-year period, the price return was 347.43%, with a dividend return of 0.82%, culminating in a total return of 348.25%.<BR><BR>For the 3-year period, the price return was 1133.21%, the dividend return was 2.76%, resulting in a total return of 1135.97%.<BR><BR>In the last 4 years, the price return was 522.76%, with a dividend return of 1.61%, leading to a total return of 524.37%.<BR><BR>Over the past 5 years, the price return was 3142.13%, with a dividend return of 6.26%, resulting in a total return of 3148.39%.<BR><BR>Overall, Neuland Laboratories Ltd has declared a significant dividend, and while the recent returns have shown volatility, particularly in the short term, the longer-term performance indicates substantial growth in total returns, driven largely by price appreciation.